Theravance Biopharma Inc. (TBPH) Business Metric Overview - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Theravance Biopharma Inc.

    NASDAQ: TBPH · Real-Time Price · USD
    13.73
    -0.19 (-1.36%)
    At close: Sep 09, 2025, 2:53 PM

    Theravance Biopharma Revenue Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018
    Collaborative Arrangement Revenue Revenue 18.7M 20.42M 23.34M 21.77M 19.09M 19.33M 21.23M 20.41M 19.3M 16.4M 18.7M 17.2M 15.3M 1.98M 3.87M 7.08M 7.26M 5.49M 6.63M 9.58M 8.84M 7.65M 5.34M 10.05M 8.99M 16K
    Collaborative Arrangement Revenue Revenue Growth -8.45% -12.51% +7.23% +14.05% -1.26% -8.93% +3.97% +5.77% +17.68% -12.30% +8.72% +12.42% +672.73% -48.86% -45.33% -2.45% +32.31% -17.25% -30.80% +8.47% +15.50% +43.31% -46.87% +11.77% +56081.25% n/a
    License Revenue 7.5M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 1.5M 10M n/a 18.5M n/a n/a n/a n/a
    License Revenue Growth n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a -100.00% -85.00% n/a -100.00% n/a n/a n/a n/a n/a
    YUPELRI Monotherapy Revenue 23.22M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    YUPELRI Monotherapy Revenue Growth n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Operating Expense Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 18.43M 18.37M 18.5M 16.88M 17.06M 16.74M 15.49M 16.14M 19.28M 19.18M 16.73M 16.28M 16.99M 23.64M 21.52M 21.3M 25.93M 30.55M 30.05M 27.5M 24.78M 26.32M 33.05M 25.62M 22.23M 25.19M 25.46M 21.89M 25.01M 24.7M 29.52M 20.94M 24.34M 20.79M 20.37M 20.29M 20.26M 23.6M 24.06M 22.84M 21.55M 21.75M
    Selling, General, and Administrative Revenue Growth +0.33% -0.71% +9.64% -1.06% +1.88% +8.07% -4.03% -16.27% +0.50% +14.63% +2.81% -4.17% -28.14% +9.86% +1.02% -17.86% -15.12% +1.65% +9.29% +10.98% -5.87% -20.34% +28.98% +15.27% -11.75% -1.06% +16.30% -12.46% +1.23% -16.33% +40.97% -13.95% +17.09% +2.06% +0.39% +0.12% -14.13% -1.94% +5.34% +6.03% -0.93% n/a
    Research and Development Revenue 10.49M 11.45M 9.45M 9.27M 9.95M 8.97M 8.31M 8.31M 9.43M 14.57M 15.35M 9.87M 15.57M 23.25M 31.23M 43.74M 51.09M 67.6M 65.17M 67.37M 62.4M 66.01M 67.03M 52.01M 46.4M 53.82M 52.27M 52.69M 48.62M 47.77M 51.05M 39.34M 42.93M 40.56M 42.01M 31.95M 32.07M 35.68M 32.4M 30.37M 30.38M 36.02M
    Research and Development Revenue Growth -8.40% +21.15% +2.00% -6.89% +10.99% +7.87% +0.04% -11.82% -35.32% -5.05% +55.54% -36.63% -33.04% -25.53% -28.61% -14.39% -24.42% +3.74% -3.27% +7.96% -5.47% -1.51% +28.88% +12.08% -13.79% +2.96% -0.80% +8.37% +1.79% -6.44% +29.76% -8.35% +5.82% -3.45% +31.49% -0.37% -10.12% +10.11% +6.70% -0.03% -15.66% n/a

    Add to Watchlist